期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

冠状动脉粥样硬化PCI术后肝素诱导血小板减少症的诊治 被引量：2

下载PDF
导出
摘要 肝素是一种最常用的药物并且在世界范围内有着较为广泛的应用，肝素在机体中少量自然产生，其活动机制是通过抑制等离子体辅助因子及凝血酶，从而使凝血酶及X因子、IX因子失活。而在临床上，则是将从动物组织中提取的肝素应用于人体，以达到治疗和预防血栓栓塞性疾病的目的。
作者 范思佳 高会远 张永飞 陈丽娟
机构地区 吉林大学第二医院心血管内科
出处 《中国实验诊断学》 2014年第10期1731-1733,共3页 Chinese Journal of Laboratory Diagnosis
关键词 肝素诱导 冠状动脉粥样硬化 血小板减少症 PCI术后 血栓栓塞性疾病 诊治 IX因子 世界范围
分类号 R543.5 [医药卫生—心血管疾病] R558.2 [医药卫生—血液循环系统疾病]
  • 相关文献

参考文献18

  • 1Hirsh J, Raschke R, CM. Heparin and low-molecular-weight hepatin:the seventh ACCP Conference on Antithrombotic and Throm- bolytic Therapy[J]. Chest. 2004; 126(3 Suppl) :188.
  • 2Kelton JG, MD. The pathophysiology of heparin-indueed thrombocytopenia biological basis for treatment [J]. Chest, 2005; 127 (Supply) : 9.
  • 3Liu CY, Battaglia M, Lee SH, et al. Platelet factor D differentially modulates CD4 + (Nonregulatory) T cell[J]. J Immuna, 2005 ; 174:2680.
  • 4Reilly MP, Taylor SM, Hartm an HK, et al. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet4 and platelet activation through Fcγ II a[J].Blood, 2001 , 98 : 2422.
  • 5Greinacher A,Famer B, K roll H, et al Clinical features of hepa rin-induced thrombocytopenia including risk factors for thrombosis A retrospective analysis of 408 patients[J]. Thromb Haenost, 2005,94(1) :132.
  • 6Lubenow N,Kempf R,Eichner A. Heparin-imduced thrombocyto penia:temporal pattern of thrombbcytopenia in relation to initial use or reexposure to heparin[J]. Chest,2002,122(1) :37.
  • 7LoGK, JuhlD, Warkentin TE, et al. Evaluation of pretest clinical score(4T) for the diagnosis of heparin induced thrombocytopenia in two clinical settings[J]. J Thromb Haemost,2006,4(4):759.
  • 8Warkentin TE, Aird WC, Rand JH. Platelet-endothelial interac tions: sepsis, HIT, and antiphospholipid syndrome. Hematolog (Am Soc Hematol Educ Prog),2003,487-519.
  • 9Warkentin TE, Kelton JG. Temporal aspects of heparininduced thrombocytopenia[J]. N Engl J Med,2001,344(17) : 1286.
  • 10Greinacher A, Juhl D, Strobel U, et al. Heparin-induced throm bocytopenia :a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/hepa rin antibodies of the IgG,IgM,and IgA classes[J]. J Thromb H aemost,2007 ,5(8) :1666.

二级参考文献41

  • 1[1]Menajovsky LB.Heparin-induced thrombocytopenin:clinical manifestations and management strategies[J].Am J Med,2005;118 (Suppl.8A):S21-S30.
  • 2[2]Weismann RE,Tobin RW.Arterial embolism occurring during systemic heparin therapy[J].AMA Arch Surg,1958;76:219-225.
  • 3[3]Kelton JG.The pathophysiology of heparin-induced thrombocytopenia:biological basis for treatment[J].Chest,2005;127(Supply):S9-S20.
  • 4[4]Franehini M.Heparin-induced thrombocytopenia:an update[J].Thromb J,2005;3:14-19.
  • 5[5]Lubenow N,Kempf R,Eichner A,et al.Heparin-induced thromliocytoponia:temporal pattern of thromboeytopenia in relation to initial use or reexposure to heparin[J].Chest,2002;122:37-42.
  • 6[6]Rice L,Attisha WK,Drexler A,et al.Delayed-onset heparin-induced thrombocytopenia[J].Ann Intern Med,2002;136:210-215.
  • 7[7]Liu CY,Battaglia M,Lee SH,et al.Platelet factor D differentially modulates CD4 + CD25 + (Regulatory)venus CD4 + CD25-(Nonregulatory) T cell[J].J Immuno,2005;174:2680-2686.
  • 8[8]Reilly MP,Taylor SM,Hartman NK,et al.Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet 4 and platelet activation through FcγR Ⅱ A[J].Blood,2001;98:2422-2447.
  • 9[9]Rauova L,Poncz M,MeKenzie SE,et al.Ultralarge complexs of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopania[J].Blood,2005;105:131-138.
  • 10[10]Warkentin TE,Greinacher A.Heparin-induced thrombocytopenia:Recognition,treatment,and prevention.The seventh ACCP conference on antithrombotic and thrombolytic therapy[J].Chest,2004;126(Suppl.):S311-S337.

共引文献39

同被引文献17

引证文献2

中国实验诊断学
2014年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部